Dr. Hammers on Study of HyperAcute Renal Immunotherapy in RCC
Hans Hammers, MD, PhD
Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses HyperAcute Renal (HAR) immunotherapy in patients with renal cell carcinoma (RCC).
In a phase I study of alpha-1, 3-galactosyltransferase-expressing allogeneic RCC immunotherapy, patients with metastatic RCC were given injections of HAR for 4 weeks (150 x106 cells/300 x106 cells intradermally). This was followed by 10 weeks of bi-weekly injections.
HAR was well tolerated in this population, says Hammers, and RCC was deemed an appropriate tumor type to target with combination immunotherapy.